CRIS vs. CDTX, NTGN, XFOR, CDXS, ACHV, RIGL, RGLS, SGMO, VSTM, and FBIO
Should you be buying Curis stock or one of its competitors? The main competitors of Curis include Cidara Therapeutics (CDTX), Neon Therapeutics (NTGN), X4 Pharmaceuticals (XFOR), Codexis (CDXS), Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Sangamo Therapeutics (SGMO), Verastem (VSTM), and Fortress Biotech (FBIO). These companies are all part of the "medical" sector.
Cidara Therapeutics (NASDAQ:CDTX) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.
Cidara Therapeutics has a net margin of -73.46% compared to Cidara Therapeutics' net margin of -486.45%. Curis' return on equity of -201.62% beat Cidara Therapeutics' return on equity.
Curis received 249 more outperform votes than Cidara Therapeutics when rated by MarketBeat users. However, 70.24% of users gave Cidara Therapeutics an outperform vote while only 67.65% of users gave Curis an outperform vote.
Cidara Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.59, meaning that its stock price is 259% more volatile than the S&P 500.
In the previous week, Cidara Therapeutics had 3 more articles in the media than Curis. MarketBeat recorded 4 mentions for Cidara Therapeutics and 1 mentions for Curis. Cidara Therapeutics' average media sentiment score of 1.87 beat Curis' score of 0.87 indicating that Curis is being referred to more favorably in the news media.
Cidara Therapeutics presently has a consensus price target of $71.25, indicating a potential upside of 461.47%. Curis has a consensus price target of $37.33, indicating a potential upside of 260.36%. Given Curis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cidara Therapeutics is more favorable than Curis.
Cidara Therapeutics has higher revenue and earnings than Curis. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 7.4% of Cidara Therapeutics shares are held by company insiders. Comparatively, 5.7% of Curis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Cidara Therapeutics beats Curis on 13 of the 18 factors compared between the two stocks.
Get Curis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
